$CCCC
C4 Therapeutics, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021056223 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $8.500M $8.450M $16.49M
YoY Change 0.59%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.452M $2.860M $5.611M
YoY Change 195.52%
% of Gross Profit
Research & Development $24.30M $23.94M $33.37M
YoY Change 1.53% 84.85%
% of Gross Profit
Depreciation & Amortization $330.0K $420.0K $416.0K
YoY Change -21.43% -44.53%
% of Gross Profit
Operating Expenses $32.75M $26.80M $39.68M
YoY Change 22.23% 74.4%
Operating Profit -$24.25M -$18.35M
YoY Change 32.18% 83.47%
Interest Expense -$429.0K -$3.490M $182.0K
YoY Change -87.71%
% of Operating Profit
Other Income/Expense, Net -$429.0K -$3.653M -$25.00K
YoY Change -88.26% -755.83%
Pretax Income -$24.68M -$22.00M -$10.96M
YoY Change 12.19% 132.97%
Income Tax $0.00 -$167.0K -$168.0K
% Of Pretax Income
Net Earnings -$24.68M -$21.84M -$10.79M
YoY Change 13.04% 116.32%
Net Earnings / Revenue -290.39% -258.4% -65.47%
Basic Earnings Per Share -$0.51 -$17.55 -$9.28
Diluted Earnings Per Share -$509.0K -$525.6K -$546.5K
COMMON SHARES
Basic Shares Outstanding 48.49M shares
Diluted Shares Outstanding 48.49M shares

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $163.0M $199.4M $211.6M
YoY Change -18.26%
Cash & Equivalents $162.7M $63.43M $107.7M
Short-Term Investments $247.5K $136.0M $103.9M
Other Short-Term Assets $5.378M $5.400M $3.300M
YoY Change -0.41%
Inventory
Prepaid Expenses
Receivables $4.845M $4.141M $8.500M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $412.3M $208.9M $223.4M
YoY Change 97.34%
LONG-TERM ASSETS
Property, Plant & Equipment $3.323M $3.580M $17.60M
YoY Change -7.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $78.19M
YoY Change
Other Assets $1.854M $502.0K $2.600M
YoY Change 269.32%
Total Long-Term Assets $95.62M $20.20M $20.20M
YoY Change 373.28%
TOTAL ASSETS
Total Short-Term Assets $412.3M $208.9M $223.4M
Total Long-Term Assets $95.62M $20.20M $20.20M
Total Assets $507.9M $229.1M $243.6M
YoY Change 121.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.745M $5.264M $5.900M
YoY Change -28.86%
Accrued Expenses $12.45M $10.70M $6.500M
YoY Change 16.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.69M $40.01M $35.10M
YoY Change 21.69%
LONG-TERM LIABILITIES
Long-Term Debt $10.59M $9.900M $9.700M
YoY Change 6.95%
Other Long-Term Liabilities $49.86M $78.60M $81.80M
YoY Change -36.57%
Total Long-Term Liabilities $60.44M $88.50M $91.50M
YoY Change -31.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.69M $40.01M $35.10M
Total Long-Term Liabilities $60.44M $88.50M $91.50M
Total Liabilities $109.1M $128.5M $126.6M
YoY Change -15.09%
SHAREHOLDERS EQUITY
Retained Earnings -$252.1M
YoY Change
Common Stock $6.096M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $398.8M -$155.9M -$135.1M
YoY Change
Total Liabilities & Shareholders Equity $507.9M $229.1M $243.6M
YoY Change 121.7%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$24.68M -$21.84M -$10.79M
YoY Change 13.04% 116.32%
Depreciation, Depletion And Amortization $330.0K $420.0K $416.0K
YoY Change -21.43% -44.53%
Cash From Operating Activities -$18.36M -$14.45M -$31.26M
YoY Change 27.04% -142.35%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$280.0K -$80.00K
YoY Change -100.0% -93.75%
Acquisitions
YoY Change
Other Investing Activities -$100.6M -$31.99M -$103.9M
YoY Change 214.56% 598.05%
Cash From Investing Activities -$100.6M -$32.26M -$104.0M
YoY Change 211.92% 543.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 584.0K 2.500M 152.4M
YoY Change -76.64% 507833.33%
NET CHANGE
Cash From Operating Activities -18.36M -14.45M -31.26M
Cash From Investing Activities -100.6M -32.26M -104.0M
Cash From Financing Activities 584.0K 2.500M 152.4M
Net Change In Cash -118.4M -44.21M 17.10M
YoY Change 167.81% -70.35%
FREE CASH FLOW
Cash From Operating Activities -$18.36M -$14.45M -$31.26M
Capital Expenditures $0.00 -$280.0K -$80.00K
Free Cash Flow -$18.36M -$14.17M -$31.18M
YoY Change 29.56% -141.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
416427000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
873000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6027000
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-86000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.118574732
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.118574732
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.118574732
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24302000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
24933000
CY2020Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
10000
CY2021Q3 cccc Interest Expense And Amortization Of Long Term Debt Related Party
InterestExpenseAndAmortizationOfLongTermDebtRelatedParty
539000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24683000
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-86000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-429000
cccc Interest Expense And Amortization Of Long Term Debt Related Party
InterestExpenseAndAmortizationOfLongTermDebtRelatedParty
689000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24683000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22002000
CY2020Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
8447000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
25707000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23935000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68114000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58007000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8452000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2861000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24472000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8472000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
32754000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
26796000
us-gaap Operating Expenses
OperatingExpenses
92586000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24254000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18349000
us-gaap Interest And Other Income
InterestAndOtherIncome
251000
us-gaap Interest And Other Income
InterestAndOtherIncome
334000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24769000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21825000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24683000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-168000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
8000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68402000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44532000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21835000
us-gaap Net Income Loss
NetIncomeLoss
-68234000
us-gaap Net Income Loss
NetIncomeLoss
-44540000
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5212000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
10363000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68234000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
400138000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3141000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3141000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3653000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1355000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3496000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68234000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45042000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-167000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-502000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21835000
us-gaap Net Income Loss
NetIncomeLoss
-68234000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54903000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-17.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-36.76
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48490533
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45163444
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1493521
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
280791000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
166000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3845000
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-107000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-20971000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-19000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
263705000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
169483000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
539000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5175000
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
25000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22580000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
80000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24683000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27047000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1540902
us-gaap Share Based Compensation
ShareBasedCompensation
15159000
us-gaap Share Based Compensation
ShareBasedCompensation
713000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8425000
us-gaap Profit Loss
ProfitLoss
-68234000
us-gaap Profit Loss
ProfitLoss
-44540000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24683000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
222000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
398780000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-111962000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
156000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
116000
CY2020Q1 cccc Adjustments To Additional Paid In Capital Repurchase Of Common Stock
AdjustmentsToAdditionalPaidInCapitalRepurchaseOfCommonStock
202000
CY2020Q1 cccc Vested Stock Option Settlement
VestedStockOptionSettlement
-728000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-11912000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-124532000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
109000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
161000
CY2020Q2 cccc Adjustments To Additional Paid In Capital Repurchase Of Common Stock
AdjustmentsToAdditionalPaidInCapitalRepurchaseOfCommonStock
-78000
CY2020Q2 cccc Vested Stock Option Settlement
VestedStockOptionSettlement
-85000
CY2020Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-2000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10793000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-135064000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
529000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
436000
CY2020Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
10000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21835000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-155924000
us-gaap Depreciation
Depreciation
1169000
us-gaap Depreciation
Depreciation
1252000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
980000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
910000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1032000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-8000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
540000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
229000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3141000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
361000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-482000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1120000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1798000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1939000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-133000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2242000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3156000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-772000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-651000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9990000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61294000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45656000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
263569000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
392324000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
135979000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1168000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
359000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-129923000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136338000
CY2021Q2 cccc Net Proceeds From Issuance Of Follow On After Deducting Underwriting Discounts Commission And Expenses
NetProceedsFromIssuanceOfFollowOnAfterDeductingUnderwritingDiscountsCommissionAndExpenses
169500000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
480300000
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-8.4335
cccc Payments Of Follow On Offering Cost
PaymentsOfFollowOnOfferingCost
11300000
cccc Proceeds From Issuance Of Follow On Offering
ProceedsFromIssuanceOfFollowOnOffering
169465000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1578000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
764000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
286000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
2446000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4500000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
145525000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
500000
cccc Proceeds From Issuance Of Long Term Debt And Warrant
ProceedsFromIssuanceOfLongTermDebtAndWarrant
11973000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
210000
cccc Payments For Vested Stock Option Settlement
PaymentsForVestedStockOptionSettlement
727000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
177000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
170934000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
154879000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-20283000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-27115000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184304000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93126000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
164021000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66011000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
164021000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66011000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1276000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2577000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
162745000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63434000
us-gaap Interest Paid Net
InterestPaidNet
1070000
us-gaap Interest Paid Net
InterestPaidNet
461000
cccc Aggregate Exercise Price Of Warrant Net Exercised Related Party
AggregateExercisePriceOfWarrantNetExercisedRelatedParty
3002000
cccc Initial Public Offering Costs In Accrued Expenses
InitialPublicOfferingCostsInAccruedExpenses
474000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000
cccc Stock Option Exercises Included In Prepaid And Other Current Assets
StockOptionExercisesIncludedInPrepaidAndOtherCurrentAssets
33000
cccc Fair Value Of Warrants Issued In Connection With Debt Issuance
FairValueOfWarrantsIssuedInConnectionWithDebtIssuance
5465000
us-gaap Profit Loss
ProfitLoss
-68200000
us-gaap Profit Loss
ProfitLoss
-44500000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252100000
CY2021Q3 cccc Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2021Q3 cccc Fair Value Liabilities Level3 To Level1 Transfers Amount
FairValueLiabilitiesLevel3ToLevel1TransfersAmount
0
CY2021Q3 cccc Fair Value Liabilities Level1 To Level3 Transfers Amount
FairValueLiabilitiesLevel1ToLevel3TransfersAmount
0
CY2021Q3 cccc Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the condensed consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, amounts and timing of revenues recognized under the Company’s research and development collaboration arrangements and accrued research and development expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</p>
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
479962000
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 cccc Fair Value Liabilities Level3 To Level2 Transfers Amount
FairValueLiabilitiesLevel3ToLevel2TransfersAmount
0
CY2021Q3 cccc Fair Value Liabilities Level2 To Level3 Transfers Amount
FairValueLiabilitiesLevel2ToLevel3TransfersAmount
0
CY2021Q3 cccc Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
CY2021Q3 cccc Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8955000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6801000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5632000
CY2021Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
317672000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
158000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
317517000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
189949000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
189962000
cccc Number Of Marketable Securities
NumberOfMarketableSecurities
91
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
247500
CY2021Q3 cccc Individual Securities
IndividualSecurities
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10124000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3323000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3323000
CY2021Q3 us-gaap Depreciation
Depreciation
330000
CY2020Q3 us-gaap Depreciation
Depreciation
420000
us-gaap Depreciation
Depreciation
1169000
us-gaap Depreciation
Depreciation
1252000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y7M6D
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2410000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2482000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2557000
CY2021Q3 cccc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
6277000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16634000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4537000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12097000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
568000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2340000
CY2021Q3 cccc Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6871000
CY2020Q4 cccc Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3799000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3444000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3724000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
955000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1532000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
201000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
469000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11471000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9524000
CY2021Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
8500000
CY2020Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
8447000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
713000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
25707000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
24933000
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
4845000
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
32294000
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
38936000
CY2021Q3 us-gaap Deferred Revenue
DeferredRevenue
71230000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
4484000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
27603000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
53617000
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
81220000
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7479000
CY2020Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4889000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
17060000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
13697000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
713000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
227000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3000000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9500000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12500000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1912000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
10588000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-8.4335
CY2020Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
100000
CY2020Q1 cccc Payments For Relinquishment Of Right To Purchase Common Stock Upon Exercise Of Stock Options
PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions
700000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6086000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
436000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15159000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5029364
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1629304
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
41.85
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
380688
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
395676
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.55
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5882304
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.29
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1120931
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.48
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5882304
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
21.29
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
72800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-167000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-502000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5882304
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33050017
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-8.4335
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24683000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21835000
us-gaap Net Income Loss
NetIncomeLoss
-68234000
us-gaap Net Income Loss
NetIncomeLoss
-44540000
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5212000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
10363000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24683000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27047000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68234000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54903000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48490533
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1540902
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45163444
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1493521
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-17.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-36.76

Files In Submission

Name View Source Status
0001564590-21-056223-index-headers.html Edgar Link pending
0001564590-21-056223-index.html Edgar Link pending
0001564590-21-056223.txt Edgar Link pending
0001564590-21-056223-xbrl.zip Edgar Link pending
cccc-10q_20210930.htm Edgar Link pending
cccc-10q_20210930_htm.xml Edgar Link completed
cccc-20210930.xsd Edgar Link pending
cccc-20210930_cal.xml Edgar Link unprocessable
cccc-20210930_def.xml Edgar Link unprocessable
cccc-20210930_lab.xml Edgar Link unprocessable
cccc-20210930_pre.xml Edgar Link unprocessable
cccc-ex311_8.htm Edgar Link pending
cccc-ex312_6.htm Edgar Link pending
cccc-ex321_7.htm Edgar Link pending
cccc-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending